Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes

Trial Profile

Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Colecalciferol (Primary) ; Etanercept (Primary) ; GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms EDCR IIa
  • Sponsors Diamyd Medical AB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 According to a Diamyd Medical media release, the next evaluation point for this trial is when all patients have completed their 15-month visit, which should be around mid-December 2017. The results are expected to be presented in the first quarter of 2018.
    • 19 May 2017 According to a Diamyd Medical media release, 6-month results from this trial will be presented at the Scandinavian Society for the Study of Diabetes meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top